Coherence, a brain-implant cancer detection and intervention platform, secured a $45 million seed round aimed at accelerating its first chronic human trial in glioblastoma. The investment includes OpenAI Startup Fund and Founders Fund, alongside participation from Lux Capital and 8VC, and involvement from Neuralink’s head neurosurgeon. Coherence’s SOMA implant monitors tumor-associated electrical signals and can deliver stimulation, paired with a removable wearable and app-based tracking. The funding matters for translational investors and regulators because it raises the bar for non-traditional, device-plus-data oncology evidence generation—moving from short intraoperative testing toward chronic implantation and longer-term clinical outcomes.